Capricor Therapeutics Provides Update on ALLSTAR Trial
Unlikely to Achieve Primary Efficacy Endpoint of Change in Infarct Size in Patients Following Heart Attack
Capricor to Focus on Potential Registration Program in Duchenne Muscular Dystrophy
Company to Hold Conference Call Today at 5:00 AM PDT / 8:00 ... Regenerative Medicine, Cardiology Capricor Therapeutics, ALLSTAR Trial, allogeneic cardiosphere-derived cells
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Cardiology | Conferences | Heart | Heart Attack | Muscular Dystrophy | Pharmaceuticals | Reflex Sympathetic Dystrophy